Chronic AMPK activity dysregulation produces myocardial insulin resistance in the human Arg302Gln-PRKAG2 glycogen storage disease mouse model

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-9

  Thorn, Stephanie L ^a,b   Gollob, Michael H ^b   Harper, Mary Ellen ^b   Beanlands, Rob S ^a,b   Dekemp, Robert A ^a   Dasilva, Jean N ^a,b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Echocardiography; FDG; Glucose; Patlak; Positron emission tomography

Indexed keywords

ADENYLATE KINASE; ADENYLATE KINASE ALPHA; ARGININE; FLUORODEOXYGLUCOSE F 18; GLUTAMINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOGEN; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; GENE; GENE MUTATION; GENOTYPE; GLUCOSE TRANSPORT; GLYCOGEN ANALYSIS; GLYCOGEN MUSCLE LEVEL; GLYCOGEN STORAGE DISEASE; HEART DISEASE; HEART MUSCLE; HEART RATE; HEART VENTRICLE HYPERTROPHY; HORMONAL REGULATION; HUMAN; IN VIVO STUDY; INSULIN RESISTANCE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRKAG2 CARDIAC SYNDROME; PRKAG2 GENE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE; SYSTOLIC BLOOD PRESSURE; TISSUE DISTRIBUTION; TRANSGENE;

EID: 84881233417     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-48     Document Type: Article

References (25)

1. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L: Insulin resistance and risk of congestive heart failure. JAMA 2005, 294:334-341.
2. Raher MJ, Thibault HB, Buys ES, Kuruppu D, Shimizu N, Brownell AL, Blake SL, Rieusset J, Kaneki M, Derumeaux G, Picard MH, Bloch KD, Scherrer-Crosbie M: A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload. Am J Physiol Heart Circ Physiol 2008, 295:H2495-H2502.
3. Horman S, Beauloye C, Vanoverschelde JL, Bertrand L: AMP-activated protein kinase in the control of cardiac metabolism and remodeling. Curr Heart Fail Rep 2012, 9:164-173.
4. Longnus SL, Segalen C, Giudicelli J, Sajan MP, Farese RV, Van Obberghen E: Insulin signalling downstream of protein kinase B is potentiated by 5' AMP-activated protein kinase in rat hearts in vivo. Diabetologia 2005, 48:2591-2601.
5. Ginion A, Auquier J, Benton CR, Mouton C, Vanoverschelde JL, Hue L, Horman S, Beauloye C, Bertrand L: Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake. Am J Physiol Heart Circ Physiol 2011, 301:H469-H477.
6. Yang J, Holman GD: Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis. Endocrinology 2006, 147:2728-2736.
7. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A: Ali Hassan AS, Ahmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R: Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001, 344:1823-1831.
8. Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, Roberts R: Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001, 104:3030-3033.
9. Gollob MH, Roberts R: AMP-activated protein kinase and familial Wolff-Parkinson-White syndrome: new perspectives on heart development and arrhythmogenesis. Eur Heart J 2002, 23:679-681.
10. Gollob MH: Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome. Biochem Soc Trans 2003, 31:228-231.
11. Gollob MH, Green MS, Tang AS, Roberts R: PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 2002, 17:229-234.
12. Gollob MH, Green M, Veinot JP: Altered AMP-activated protein kinase activity and pathologic cardiac disease. Heart and Metabolism 2006, 32:28-31.
13. Ha AC, Renaud JM, Dekemp RA, Thorn S, Dasilva J, Garrard L, Yoshinaga K, Abraham A, Green MS, Beanlands RS, Gollob MH: In vivo assessment of myocardial glucose uptake by positron emission tomography in adults with the PRKAG2 cardiac syndrome. Circ Cardiovasc Imaging 2009, 2:485-491.
14. Sidhu JS, Rajawat YS, Rami TG, Gollob MH, Wang Z, Yuan R, Marian AJ, DeMayo FJ, Weilbacher D, Taffet GE, Davies JK, Carling D, Khoury DS, Roberts R: Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. Circulation 2005, 111:21-29.
15. Simoes MV, Egert S, Ziegler S, Miyagawa M, Reder S, Lehner T, Nguyen N, Charron MJ, Schwaiger M: Delayed response of insulin-stimulated fluorine-18 deoxyglucose uptake in glucose transporter-4-null mice hearts. J Am Coll Cardiol 2004, 43:1690-1697.
16. Thorn S, DeKemp R, Dumouchel T, Klein R, Renaud J, Wells G, Gollob M, Beanlands R, Dasilva J: Repeatable non-invasive imaging of FDG PET in the mouse myocardium: evaluation of tracer kinetics in a type 1 diabetes model. J Nucl Med 2013. in press.
17. Patlak CS, Blasberg RG, Fenstermacher JD: Graphical evaluation of bloodto-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983, 3:1-7.
18. Zhou H, Zhang T, Bogdani M, Oseid E, Parazzoli S, Vantyghem MC, Harmon J, Slucca M, Robertson RP: Intrahepatic glucose flux as a mechanism for defective intrahepatic islet alpha-cell response to hypoglycemia. Diabetes 2008, 57:1567-1574.
19. Zaha VG, Young LH: AMP-activated protein kinase regulation and biological actions in the heart. Circ Res 2012, 111:800-814.
20. Coven DL, Hu X, Cong L, Bergeron R, Shulman GI, Hardie DG, Young LH: Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise. Am J Physiol Endocrinol Metab 2003, 285:E629-E636.
21. Folmes KD, Chan AY, Koonen DP, Pulinilkunnil TC, Baczko I, Hunter BE, Thorn S, Allard MF, Roberts R, Gollob MH, Light PE, Dyck JR: Distinct early signaling events resulting from the expression of the PRKAG2 R302Q mutant of AMPK contribute to increased myocardial glycogen. Circ Cardiovasc Genet 2009, 2:457-466.
22. Kreissl MC, Stout DB, Wong KP, Wu HM, Caglayan E, Ladno W, Zhang X, Prior JO, Reiners C, Huang SC, Schelbert HR: Influence of dietary state and insulin on myocardial, skeletal muscle and brain [F]-fluorodeoxyglucose kinetics in mice. EJNMMI Res 2011, 1:8.
23. Towler MC, Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100:328-341.
24. Kraegen EW, Saha AK, Preston E, Wilks D, Hoy AJ, Cooney GJ, Ruderman NB: Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. Am J Physiol Endocrinol Metab 2006, 290:E471-E479.
25. Saha AK, Xu XJ, Balon TW, Brandon A, Kraegen EW, Ruderman NB: Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation? Cell Cycle 2010, 10:3447-3451.